Comparative Pharmacology
Head-to-head clinical analysis: GENTAMICIN versus KANAMYCIN SULFATE.
Head-to-head clinical analysis: GENTAMICIN versus KANAMYCIN SULFATE.
GENTAMICIN vs KANAMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis; bactericidal against gram-negative aerobes.
Aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing mRNA misreading.
5-7 mg/kg/day IV or IM in divided doses every 8 hours; for serious infections, up to 5 mg/kg/day IV in 3 divided doses.
15 mg/kg/day IM or IV divided every 8-12 hours; typical adult dose: 500 mg IM every 12 hours or 7.5 mg/kg every 12 hours. Maximum total daily dose: 1.5 g.
None Documented
None Documented
2-3 hours in adults with normal renal function; prolonged to 24-48 hours in anuria; adjust dosing based on renal function.
Clinical Note
moderateGentamicin + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Digitoxin
"The serum concentration of Digitoxin can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Deslanoside
"The serum concentration of Deslanoside can be decreased when it is combined with Gentamicin."
Clinical Note
moderateGentamicin + Acetyldigitoxin
Terminal elimination half-life is 2-4 hours in adults with normal renal function; prolonged to 30-60 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (glomerular filtration): 90-95% unchanged in urine over 24 hours; biliary/fecal: <2%.
Renal excretion of unchanged drug accounts for 80-90% of elimination; minor biliary excretion (<1%) and fecal elimination (<1%).
Category D/X
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic
"The serum concentration of Acetyldigitoxin can be decreased when it is combined with Gentamicin."